Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
Anchal GhaiAlexander ZheleznyakMatt MixdorfJulie O'NealJulie RitcheyMichael RettigJohn DiPersioMonica ShokeenSamuel AchilefuPublished in: European journal of nuclear medicine and molecular imaging (2020)
These data demonstrate the feasibility of [89Zr]DFO-elotuzumab as a companion diagnostic for CS1-targeted therapies.